Success Metrics

Active Trials
3(43%)

Phase Distribution

Ph early_phase_1
3
43%
Ph phase_1
3
43%

Phase Distribution

6

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
3(50.0%)
Phase 1Safety & dosage
3(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Terminated(1)
Other(2)

Detailed Status

unknown2
Recruiting2
Active, not recruiting1
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 13 (50.0%)
Phase 13 (50.0%)

Trials by Status

unknown229%
active_not_recruiting114%
not_yet_recruiting114%
recruiting229%
withdrawn114%

Recent Activity

3 active trials
Showing 5 of 7
withdrawn

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

NCT06508346
active_not_recruitingphase_1

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

NCT06222853
recruitingearly_phase_1

Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies

NCT06532630
not_yet_recruitingearly_phase_1

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

NCT06420154
recruitingearly_phase_1

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

NCT06375161
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06508346

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

Withdrawn
NCT06222853Phase 1

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Active Not Recruiting
NCT06532630Early Phase 1

Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies

Recruiting
NCT06420154Early Phase 1

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Not Yet Recruiting
NCT06375161Early Phase 1

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

Recruiting
NCT03030976Phase 1

A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)

Unknown
NCT02672501Phase 1

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

Unknown

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7